

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

EQA round: BM2/19 - Bone Markers

Dead line: 02.08.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(431) Parathyroid hormone (PTH)					23							22	21	95%
Samples and groups	[pmol/L]													
Sample A		7,05	1,3	18	23							22	21	95%
(1) Immunochemical meth.; (60) Roche		6,51	0,45	7,0	14	0	CVPG	6,45	0,20	23%	4,96	7,94	14	
(1) Immunochemical meth.; (179) Siemens		7,89	0,91	12	5	0	CVPG	8,32	0,33	23%	6,4	10,3	5	
Other					4	1							3	
								2x 1/1, 1x 1/12, 1x 1/29						
Sample B		20,9	3,2	16	23							22	22	100%
(1) Immunochemical meth.; (60) Roche		19,8	0,98	5,0	14	0	CVPG	19,8	0,46	23%	15,2	24,4	14	
(1) Immunochemical meth.; (179) Siemens		22,9	1,9	8,4	5	0	CVPG	23,9	0,95	23%	18,4	29,4	5	
Other					4	0							3	
								2x 1/1, 1x 1/12, 1x 1/29						
(432) Collagen telopeptide CTx-beta					16							15	14	93%
Samples and groups	[ng/L]													
Sample A		289	22	7,6	16							15	15	100%
(1) Immunochemical meth.; (60) Roche		292	20	6,8	15	0	CVPG	306	5,4	17%	253	359	15	
Other					1	0							0	
								1x 1/183						
Sample B		672	56	8,4	16							15	14	93%
(1) Immunochemical meth.; (60) Roche		679	49	7,3	15	0	CVPG	710	12	17%	589	831	15	
Other					1	0							0	
								1x 1/183						
(433) P1NP					13							13	12	92%
Samples and groups	[µg/L]													
Sample A		29,6	2,6	8,6	13							13	13	100%
(1) Immunochemical meth.; (60) Roche		29,6	2,6	8,6	13	0	CVPG	30	0,59	20%	24	36	13	
Sample B		194	20	10	13							13	12	92%
(1) Immunochemical meth.; (60) Roche		194	20	10	13	0	CVPG	196	5,1	20%	156	236	13	
(434) Osteocalcin					17							15	13	87%
Samples and groups	[µg/L]													
Sample A		18,3	1,7	9,1	17							15	13	87%
(1) Immunochemical meth.; (60) Roche		18,5	1,1	5,8	14	0	CVPG	18,8	0,27	13%	16,3	21,3	14	
Other					3	0							1	
								1x 1/24, 1x 1/29, 1x 1/164						
Sample B		99,3	7,9	7,9	17							15	14	93%
(1) Immunochemical meth.; (60) Roche		100	5,8	5,8	14	0	CVPG	102	1,6	13%	88,7	116	14	
Other					3	0							1	
								1x 1/24, 1x 1/29, 1x 1/164						
(435) 25-hydroxyvitamin D					25							22	21	95%
Samples and groups	[nmol/L]													
Sample A		75,6	13	17	25							22	21	95%
(1) Immunochemical meth.; (256) Roche (2)		78,1	7,9	10	18	0	CVPG	80	2,9	33%	53,6	107	18	
Other					7	0							4	
								3x 1/1, 1x 1/12, 1x 1/40, 1x 1/149, 1x 2/998						
Sample B		169	17	10	25							22	21	95%
(1) Immunochemical meth.; (256) Roche (2)		172	14	8,4	18	0	CVPG	175	6,3	33%	117	233	18	
Other					7	0							4	
								3x 1/1, 1x 1/12, 1x 1/40, 1x 1/149, 1x 2/998						

st_kn_p

End of report

Printed: 14.08.2019